Archive

Neovasc Reducer™ Featured In FOCUS Magazine

NASDAQ, TSX: NVCN VANCOUVER, CA, and BERLIN, DE, November 26, 2019 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of...

Read More

Neovasc Tiara™ Progress Highlighted at PCR London Valves 2019

 NASDAQ, TSX: NVCN   VANCOUVER, November 19, 2019 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced that...

Read More

Neovasc Announces Third Quarter 2019 Financial Results

NASDAQ, TSX: NVCN Recent Highlights  Delivered continued revenue growth for Neovasc ReducerTM (“Reducer”) Reducer added to the European Society of Cardiology Practice Guidelines for the treatment of refractory angina Reducer featured at the 40th Annual National Congress of the Italian Society of Interventional Cardiology Announced Norman...

Read More